Protalix Biotherapeutics Is Eligible To Receive A $20M Milestone Payment From Its Commercial Partner, Chiesi Global Rare Diseases, A Business Unit Of The Chiesi Group, Triggered By Fda Approval Of Elfabrio (Pegunigalsidase Alfa-Iwxj) For Fabry Disease
Benzinga Newsdesk - May 18, 2023, 6:52AM